Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has demonstrated significant potential for growth, particularly through the expansion of its Cortrophin sales force, which has been a key contributor to its success. The company’s commitment to leveraging data-driven insights has not only enhanced its ability to address payer-related inquiries but has also led to increased revenue estimates for Cortrophin, indicating strong market performance. This combination of strategic investment and robust sales tracking positions ANI Pharmaceuticals for further financial flexibility and multiple expansion moving forward.

Bears say

ANI Pharmaceuticals Inc. faces several significant risks that contribute to a negative outlook on its stock, including a substantial debt load exceeding $600 million, which could constrain financial flexibility and growth initiatives. Additionally, the company is exposed to various challenges such as pricing pressures across its portfolio, reimbursement uncertainties, and potential competitive threats, all of which could adversely impact revenue. The manufacturing risks and reputational concerns, particularly related to its ACTH products, further complicate its operational stability and market perception.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.